How long can one box of Capisetinib tablets/Caposetinib be taken and how long is the course of treatment?

Capivasertib (Capivasertib) is an oral small molecule pan-AKT inhibitor, mainly used to treat certain types of breast cancer , especially in patients with HR-positive, HER2-negative advanced breast cancer with specific mutations in PIK3CA, AKT1 or PTEN genes. Currently, the drug has just been approved by the National Medical Products Administration (NMPA) in mainland China, so it is temporarily unavailable for purchase in local pharmacies or hospitals. However, it has completed marketing registration in Europe and the United States. If patients need to use it, they usually obtain it through overseas medical channels. Taking the European version as an example, the more common specification is 200mg*64 tablets, which provides a dosage reference for a complete cycle.

According to the current internationally recommended dosage regimen, the standard administration method of capositinib is oral administration of 400 mg twice a day, for 4 consecutive days and then 3 days off, forming a 7-day treatment cycle. This intermittent dosing design of "4 days of taking medication and 3 days of off medication" is designed to minimize the occurrence of side effects, especially metabolic side effects related to the AKT pathway, such as hyperglycemia, rash, etc., to ensure that patients obtain higher tolerance and sustained efficacy. Considering a dose of 400 mg twice a day, a total of 800 mg needs to be taken every day. If 200 mg tablets are used, 4 tablets will be taken daily, for a total of 16 tablets in 4 days. Based on this calculation, a box of 200mg*64 tablets of capositinib can be used for exactly 4 cycles, which is a complete treatment duration of 4 weeks.

As for the total length of the treatment course, there is currently no fixed period. The course of treatment is usually determined dynamically based on the patient's tolerance to the drug, efficacy evaluation (such as tumor control, imaging progression), and whether uncontrollable adverse reactions occur. In actual clinical applications, if the patient's disease does not progress and the treatment is well tolerated, doctors will recommend taking it for multiple cycles until the disease progresses or the toxicity is intolerable.

Reference materials:https://www.drugs.com/mtm/capivasertib.html